Featured Post from ChristianaCare

ChristianaCare Enhances Health Care Services for Seniors with My65+ Program and Swank Center for Memory Care in Sussex County

ChristianaCare HomeHealth Continues to Serve Seniors with Broad Array of Services

Sep 10, 2025

4 min

Priyanka Dixit-Patel, M.D.
CaptionResizeWrap TextRemove


For many older adults in Sussex County, Delaware, navigating the health care system can feel overwhelming and difficulty accessing care can create gaps in care that ultimately lead to poor health.


To help older adults more easily meet their health needs and be successful in navigating the system, ChristianaCare has brought a variety of services to Sussex County that are specially designed for this population. These include ChristianaCare’s expanding My65+ primary care program, the Swank Center for Memory Care and ChristianaCare HomeHealth—all services that work collaboratively with seniors to help them achieve their best health based on their individual needs.


Download Photos. 


ChristianaCare My65+


ChristianaCare My65+ provides specialized primary care services for people 65 and older. ChristianaCare’s My65+ services include medication management, annual Medicare visits, chronic disease management, coordination with specialists and additional consultation time with health care providers. These services are tailored to meet the specific health needs of seniors.


“I can’t express enough how wonderful the My65+ program at ChristianaCare has been for me,” said Linda Martin of Rehoboth, a patient of the My65+ Program. “When they opened the practice in Rehoboth, it made getting the care I need much more convenient. I truly appreciate how the professionals at ChristianaCare take the time to understand my health and offer support for my mother’s care. They have a memory specialist on-site who provides expert care for my mother. It feels like I’m part of a caring community.”


ChristianaCare My65+ is available at locations in Rehoboth Beach and at a new primary care practice in Milford, which began accepting My65+ patients in May.


“ChristianaCare recognizes the importance of addressing the unique health care needs of our senior community. Our focus is on delivering care that prevents diseases, manages chronic conditions and improves overall well-being, especially for older adults,” said Priya Dixit-Patel, M.D., physician executive for Core and Advanced Primary Care at ChristianaCare.


Swank Center for Memory Care


Recognizing the significant impact that memory-related conditions can have on individuals and their families, ChristianaCare’s Swank Center for Memory Care serves as a source of hope and support for those dealing with these challenges.


A dedicated team of geriatricians, nurses, social workers and other professionals collaborates with patients and their families to offer support, education and guidance throughout the diagnosis and treatment process.


“ChristianaCare has consistently been at the forefront of providing excellent patient care, and the Swank Center for Memory Care is another opportunity for us to enhance support for people 65 and older,” said Steven Huege, M.D., MSEd, The Swank Foundation Endowed Chair in Memory Care and Geriatrics at ChristianaCare.


“By designing care that meets the specific needs of older adults, we can create a better experience and achieve improved outcomes for everyone involved. This initiative is an important part of our overarching vision to provide every older adult with the best care possible.”


The Swank Center was selected by the Centers for Medicare & Medicaid Services (CMS) to participate in the new Guiding an Improved Dementia Experience (GUIDE) Model, aimed at enhancing care coordination and access to services for those living with dementia and their caregivers. Key support services will include comprehensive assessments, care coordination, respite care, a 24/7 support line and education.


With locations in Wilmington, Smyrna and Rehoboth, the Swank Center for Memory Care serves patients throughout Delaware and the surrounding region.


ChristianaCare HomeHealth


ChristianaCare HomeHealth provides a variety of nursing care for all ages in managing chronic conditions, adapting to new diagnoses, and improving daily living activities. It is the leading provider of in-home nursing care and assistance in Delaware.


“ChristianaCare HomeHealth designs a plan of care that is personalized for those we serve,” said Donna Antenucci, MHA, BSN, RN, interim president, ChristianaCare HomeHealth. “Treating older adults in their own home is a privilege and brings comfort physically and emotionally to those served and their family.


“It is truly rewarding for us as providers of home health services to enhance people’s quality of life and improve their overall well-being. We are truly honored to be a part of their journey to wellness and healing while respecting the dignity of those we serve.”


These services are available throughout the entire state and provide comprehensive care through skilled nursing, home health aides, rehabilitative services, and medical social workers. Specially trained professionals offer home care, including physical and speech therapy, to help individuals live independently and safely.


ChristianaCare HomeHealth began as a Visiting Nurse Association (VNA) in 1922 and now has more than 350 caregivers who serve patients throughout the state. Currently, there is an active daily census of about 1,500 patients. The service admits approximately 10,000 patients each year across the state.


Meeting the Needs of Sussex County’s Rapidly Growing Population


Sussex County has been designated as a “Medically Underserved Area” by the federal government, with projections showing that the population will increase from 237,000 in 2022 to over 361,000 by 2050, further intensifying the demand for primary care services.


The providers at ChristianaCare’s new Milford location will play a crucial role in addressing the growing health care needs of Sussex County.


“My65+ and Swank Center for Memory Care Services are unique programs in Sussex County that are greatly needed because of the growing senior population,” said Anthony Paul Buonanno, M.D., MBA, primary care physician at My65+ at Rehoboth Beach. “The health care infrastructure has not been able to keep up with the demand, and it is essential to provide health care services close to home for Delawareans. I am proud to be part of a program that is innovative, necessary and useful to my community.”


While ChristianaCare primary care is a relative newcomer to Sussex County, ChristianaCare already has a large primary care network in northern Delaware, southeastern Pennsylvania, southern New Jersey and Maryland.





Connect with:
Priyanka Dixit-Patel, M.D.

Priyanka Dixit-Patel, M.D.

Family Medicine Physician

Dr. Priyanka Dixit-Patel is a family medicine physician with expertise in obstetrics, gynecology, and women’s health.

Family MedicineWomen's HealthGynecology

You might also like...

Check out some other posts from ChristianaCare

3 min

Expanding Comprehensive Cancer Services to Middletown, Delaware

ChristianaCare’s Helen F. Graham Cancer Center & Research Institute is expanding access to high-quality, comprehensive cancer care for residents in Middletown and nearby communities. These services will be offered at the new Middletown Health Center, now under construction and expected to open in May 2027. “Our vision is to expand and grow our services throughout the region so that more patients can access high-quality cancer care close to home,” said Thomas Schwaab, M.D., Ph.D., Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center & Research Institute. “By bringing our full cancer-care team and advanced technology to Middletown, we can provide highly precise, coordinated treatment while maintaining the same high standard of care our patients expect.” The cancer care services offered at the Middletown Health Center will reflect the same high-quality, comprehensive care provided at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute in Newark. Patients will have access to specialists across all major cancer types, supported by the Graham Cancer Center’s participation in the National Cancer Institute Community Oncology Research Program (NCORP), which brings advanced treatments and clinical trials directly to the community. In Middletown, this means coordinated multidisciplinary treatment planning, advanced radiation therapy, infusion services, consultations with oncologists and surgeons, nurse navigation, supportive care, clinical trial participation and both in-person and virtual visit options. Advanced Technology Enhances Precision and Comfort When services open in Middletown, patients will have access to advanced radiation therapy using the Varian TrueBeam linear accelerator, one of the most sophisticated radiation therapy systems available. TrueBeam delivers highly precise, image-guided treatments for a wide range of cancers, allowing physicians to target tumors more accurately while minimizing radiation to healthy tissue. “The TrueBeam system represents a major step forward in how we deliver radiation therapy,” said Adam Raben, M.D., chair of Radiation Oncology at ChristianaCare. “Treatments that once took 30 minutes can now be completed in just a few minutes, with real-time imaging ensuring precision. This means better tumor control, fewer side effects and a more comfortable experience for patients.” A Growing Community with Expanding Health Care Needs Middletown is one of Delaware’s fastest-growing communities, with its population projected to rise 8% by 2029, nearly twice the statewide rate, according to the US Census Bureau. Since 1990, the town’s population has grown more than 550%, and the number of residents age 65 and older has increased 24% since 2020, driving demand for accessible, high-quality health care. With continued growth and an aging population, cancer service demand in Middletown is expected to increase by 11% over the next decade, according to health care forecasts from Sg2, a Vizient company, underscoring the need for expanded local care options. Expanding Access to Meet Future Cancer Care Demand By expanding services in Middletown, ChristianaCare is responding to both the region’s population growth and the increasing need for cancer care. The new site will help patients receive timely diagnosis and treatment while reducing travel time and improving coordination with the full Graham Cancer Center team. “As our community grows, so too does the need for locally accessible, state-of-the-art cancer services,” said Schwaab. “This expansion represents a pivotal investment in the health of the Middletown—Odessa—Townsend corridor and beyond.” $92 Million Investment in Middletown’s Health The $92.3 million Middletown Health Center reflects a deep investment in the health and vitality of the state. It is part of ChristianaCare’s larger plan, announced in July 2025, to invest more than $865 million in Delaware over the next three years. In addition to cancer care, the Middletown Health Center will offer a full range of services, including primary and specialty care, women’s health, behavioral health, cardiovascular care, pediatrics, neurology, imaging, diagnostics and lab testing. The center’s healing environment will also include walking trails and abundant natural light, making high-quality, convenient and coordinated care more accessible and welcoming for patients and families. The 87,000-square-foot Health Center will be located at 621 Middletown Odessa Road, next to ChristianaCare’s existing freestanding emergency department.

3 min

ChristianaCare Launches Organoid Core to Personalize Cancer Treatment

ChristianaCare’s Cawley Center for Translational Cancer Research has unveiled a first-of-its-kind organoid core in a community cancer center program. The new laboratory facility within the Helen F. Graham Cancer Center & Research Institute grows and tests living, patient-derived tumor models, giving doctors and researchers a faster, more precise way to identify the therapies most likely to work for each patient. This innovation could change how cancer is treated in Delaware and serve as a model for community centers nationwide. There are only a handful of organoid core centers, or “tumor-on-a-chip” programs, in the United States, and ChristianaCare’s is the first within a community cancer center setting. What the Organoid Core Does Tumor organoids are tiny, three-dimensional cultures grown from a patient’s tumor tissue. They preserve the genetic and molecular traits of the original tumor, making them far more accurate than traditional cell lines. “These mini-tumors enable researchers to screen drugs faster, identify new biomarkers and discover which treatments are most likely to work for each patient,” said Thomas Schwaab, M.D., Ph.D., Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center and Research Institute. “This core is a bridge between the lab and the clinic. By growing living tumor models from cells of individual patients, we can test real-world drug responses and tailor treatments for them in ways that were not possible before.” How It Advances Patient Care The organoid core strengthens the Cawley Center's research capabilities by enabling drug screening and biomarker discovery. It will bank organoids representing the wide variety of tumors seen in the community, giving scientists a realistic system for testing therapies. ChristianaCare treats more than 70 percent of cancer patients in Delaware, giving researchers unique access to treatment-naïve samples. These are tumor tissues that have not yet been exposed to chemotherapy or other therapies. Studying them provides a more accurate picture of how cancer behaves naturally and how it might respond to new treatments. Bringing a new cancer drug to patients is expensive and risky. Estimates show it can cost $1.3 to $2.8 billion, with up to a third spent on preclinical development, and only about one in 10 compounds ever reach human trials. Traditional mouse models often fail to fully mimic human tumors, making early testing less reliable. By using organoid screening, the Cawley Center can test therapies more accurately, reduce costs and failure rates and move promising treatments into clinical trials faster. Combined with existing tissue collection programs, clinical trial infrastructure and community partnerships, these resources create a direct pathway to bring lab discoveries to patients faster. Turning Point in Translational Research “Our goal is to shorten the distance between discovery and treatment,” said Nicholas J. Petrelli, M.D., director of the Cawley Center. “Too many promising drugs fail because early models do not capture the complexity of real tumors. The organoid core helps solve that problem. We can now test therapies in models that reflect the patients we actually serve.” “This is a turning point for translational research in community health,” said Jennifer Sims Mourtada, Ph.D., associate director at the Cawley Center. “Organoid technology lets us study cancer in a way that feels personal. We are not just looking at data points. We are studying living models of a patient’s tumor, which can reveal how that person’s cancer might behave or respond to treatment. This approach brings science closer to the people it is meant to help.” Looking Ahead In the coming months, the organoid core will focus on building a diverse biobank of tumors common in Delaware. Plans include collaborations with academic institutions, shared access for external researchers, and development of immune-tumor co-culture models. By combining advanced technology, strong community partnerships and direct patient access, ChristianaCare and the Cawley Center are showing how translational cancer research can thrive in a community setting, making breakthroughs not only in the lab but also in patients’ lives.

3 min

ChristianaCare Gene Editing Institute Achieves CRISPR Breakthrough That Reverses Chemotherapy Resistance in Lung Cancer

In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer. The approach restores drug sensitivity and slows tumor growth. The findings were published Nov. 13, 2025 in the online edition of Molecular Therapy Oncology. This breakthrough stems from more than a decade of research by the Gene Editing Institute into the NRF2 gene, a known driver of treatment resistance. The results were consistent across multiple in vitro studies using human lung cancer cell lines and in vivo animal models. “We’ve seen compelling evidence at every stage of research,” said Kelly Banas, Ph.D., lead author of the study and associate director of research at the Gene Editing Institute. “It’s a strong foundation for taking the next step toward clinical trials.” Potential Beyond Lung Cancer The study focused on lung squamous cell carcinoma, an aggressive and common form of non-small cell lung cancer (NSCLC) that accounts for 20% to 30% of all lung cancer cases, according to the American Cancer Society. It’s estimated that over 190,000 people in the U.S. will be diagnosed in 2025. While the research centered on this cancer type, the implications are broader. Overactive NRF2 contributes to chemotherapy resistance in several solid tumors, including liver, esophageal and head and neck cancers. The results suggest a CRISPR-based strategy targeting NRF2 could help resensitize a wide range of treatment-resistant tumors to standard chemotherapy. “This is a significant step toward overcoming one of the biggest challenges in cancer therapy — drug resistance,” Banas said. “By targeting a key transcription factor that drives resistance, we’ve shown that gene editing can re-sensitize tumors to standard treatment. We’re hopeful that in clinical trials and beyond, this is what will allow chemotherapy to improve outcomes for patients and could enable them to remain healthier during the entirety of their treatment regimen.” Targeting a Master Switch for Resistance The research zeroed in on a tumor-specific mutation, R34G, in the NRF2 gene, which acts as a master regulator of cellular stress responses. When overactive, NRF2 helps cancer cells withstand chemotherapy. Using CRISPR/Cas9, the team engineered lung cancer cells with the R34G mutation and successfully knocked out NRF2. This restored sensitivity to chemotherapy drugs such as carboplatin and paclitaxel. In animal models, tumors directly treated with CRISPR to knockout NRF2 grew more slowly and responded better to treatment. “This work brings transformational change to how we think about treating resistant cancers,” said Eric Kmiec, Ph.D., senior author of the study and executive director of the Gene Editing Institute. “Instead of developing entirely new drugs, we are using gene editing to make existing ones effective again.” Editing Reaches Threshold Levels One of the most promising discoveries was that disrupting NRF2 in just 20% to 40% of tumor cells, was enough to improve the response to chemotherapy and shrink tumors. This insight is particularly relevant for clinical use, where editing every cancer cell may not be feasible. To test therapy in mice, the researchers used lipid nanoparticles (LNPs), a non-viral method with high efficiency and low risk of unintended, off-target effects. Sequencing confirmed that the edits were highly specific to the mutated NRF2 gene, with minimal unintended changes elsewhere in the genome. “The power of this CRISPR therapy lies in its precision. It’s like an arrow that hits only the bullseye,” said Banas. “This level of specificity with minimal unanticipated genomic side effects offers real hope for the cancer patients who could one day receive this treatment.”

View all posts
Powered by